HIGHLIGHTS
-- U.S. Clinical Development Phase, part of Akili license agreement, on schedule
-- First co-development payment from Akili expected next quarter (Q3 FY22)
-- Marketing activities in India recommenced after COVID-driven delay
-- International discussions on additional agreements continued
-- Key management roles filled, and new board member added, strengthening capabilities
-- Digital health and digital therapeutics (DTx) markets growing, according to report
TALi Digital Ltd (ASX: TD1, “TALi” or “the Company”), a leading global digital health business is pleased to provide the following quarterly activities report, together with its Appendix 4C for the quarter ended 31 December 2021 (Q2 FY2022).
For more information, download the attached PDF.
Download this document
